Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIA Applauds UK Plan For Pre-Approval Use Of Coronavirus Vaccine

More Staff To Be Trained In Giving COVID-19 And Flu Vaccines

Executive Summary

The UK can already OK the use of unapproved products, but the government wants more certainty around the conditions that will be attached to any decision to make COVID-19 vaccines available before they have been licensed. Moves are also under way to reassure pharmaceutical companies about liability issues.

You may also be interested in...

UK To Go Ahead With Pre-Licensing Use Of COVID-19 Vaccines

A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded. 

The UK’s Future As Innovator In A Post-Brexit, Post-Coronavirus World

Regulatory flexibilities combined with experience in cell and gene therapy and the wider use of technologies such as AI could help to keep the post-Brexit UK at the forefront of innovation in the life sciences. A UK regulatory conference will be discussing these and other key issues next week.

Coronavirus Notebook: UK Reveals Plans For Pre-Approval Use Of COVID-19 Vaccine

The UK government is proposing to take the "very unusual step" of making COVID-19 vaccines available before they are licensed. The international COVAX initiative is now supporting nine vaccines, and the EU and AstraZeneca have firmed up a vaccine purchase agreement.  


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts